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S U M M A R Y
Objectives: The aim of this study was to investigate the variation in hepatitis C virus (HCV) prevalence in
injection drug users (IDUs) by their gathering places, using a multilevel approach.
Methods: IDUs recruited from their gathering places were invited to respond to a questionnaire on
demographics, drug use history, injection behaviors, and methadone treatment. Dried blood spots were
collected for HCV antibody testing by ELISA. Factors associated with the anti-HCV test result were
explored by linear logistic regression, followed by the evaluation of heterogeneity between gathering
places by multilevel analysis.
Results: A total of 622 respondents from 19 gathering places in Hong Kong, recruited between August
and September 2011, were evaluated. Anti-HCV seroprevalence was 81.7% (95% conﬁdence interval
78.6–84.7%), ranging from 67% to 100% by gathering place. HCV infection was associated with current
practice of injection, needle-sharing, and midazolam injection. On multilevel analysis, there was a
modest but signiﬁcant variation in HCV antibody prevalence by gathering place, adjusted by midazolam
injection (adjusted odds ratio (AOR) 3.91) and current injection (AOR 2.88) or injection over a long
duration (AOR 3.17).
Conclusions: There was heterogeneity in HCV antibody prevalence in IDUs by gathering place, while the
inﬂuence of injection behaviors varied, suggesting interactivity between factors at the individual and
group levels.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Needle-sharing in injection drug users (IDUs) constitutes one of
the most efﬁcient transmission routes for the hepatitis C virus
(HCV).1 The reported HCV prevalence in IDUs around the world
varies greatly, with percentages as high as 60.6% in Canada,2 71.4%
in Luxembourg,3 96% in southern China,4 and 96.6% in Mexico.5
Speciﬁc factors associated with HCV transmission include the use
of contaminated injection equipment,6–8 duration of drug injec-
tion,8 and imprisonment.7 Although IDUs have often been
recruited from multiple sites,7,8 the study population is commonly
analyzed as a single group, implying a homogeneous distribution
of infection risk. As an infection driven by the practice of high-risk
behaviors, the potential inﬂuence of inter-personal relationships
and variations between social networks are often neglected. A
recent study stratifying IDUs by setting, reported HCV prevalence
that varied among outpatient drug treatment centers, inpatient
drug treatment centers, and prisons,3 lending support to the* Corresponding author. Tel.: +852 2252 8881; fax: +852 2635 4977.
E-mail address: sslee@cuhk.edu.hk (S.S. Lee).
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http://dx.doi.org/10.1016/j.ijid.2012.10.004heterogeneous pattern of HCV distribution in IDUs, even within a
small city.
To explore within-group and between-group variations, multi-
level analysis is a useful epidemiologic tool. Multilevel analysis has
been applied to examine such issues as cross-national variations in
single-mother poverty in the USA,9 and the inﬂuence of
neighborhood social capital on health-related behaviors.10 In
HCV epidemiology studies, multilevel analysis has been applied to
investigate the variations in HCV prevalence in IDUs at the
regional,11,12 temporal,13 and close-relationship levels.14–16 As
IDUs commonly interact in networks, one stratiﬁcation unit for
examining IDU behavioral variability is their social network, a unit
for which a multilevel approach has not been fully utilized. The
social network is contextual and incorporates social inﬂuences on
individual risky injection behaviors. An IDU in a large core network
has been found to be more likely to have risky injection practices
than those on the periphery.17 The social network therefore offers a
potentially important framework for classifying IDUs, so as to
identify group-level factors associated with HCV transmission.
We set out to explore the variation in HCV prevalence in IDUs in
Hong Kong, a small city (1104 km2) without signiﬁcant geographic
variation in socio-economic conditions. Among 6191 reportedses. Published by Elsevier Ltd. All rights reserved.
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HCV seroprevalence was high at 85% in IDUs,8 compared to a very
low level of 0.5% in the general population, the latter inferred from
prevalence studies in blood donors.19 It is known that IDUs tend to
gather in certain places, forming social networks distributed
throughout the territory. The aim of this study was to investigate
the variation in, and the determinants associated with, anti-HCV
seroprevalence in IDUs in gathering places, using a multilevel
approach.
2. Materials and methods
2.1. Participants and recruitment
IDUs were recruited from their gathering places in Hong Kong. A
‘gathering place’ is deﬁned as a location where IDUs frequent and
network regularly on a daily basis. Most of the gathering places are
located in the vicinity of 20 methadone clinics operated by the
Government of Hong Kong.20,21 To prepare for the study, gathering
places were mapped by trained volunteers, many of whom were
ex-drug users, familiar with the IDU community. At a gathering
place, IDUs were approached at selected timeslots and invited to
join the study if they had ever used heroin, were Chinese speaking,
and were aged 18 years. Written informed consent was obtained
from each respondent and the study was conducted anonymously.
Recruited IDUs were asked to respond to a questionnaire gathering
the following information: (1) demographics: age and gender; (2)
drug use history: year of ﬁrst heroin use and injection; (3) drug use
behavior: history of needle-sharing, heroin injection in the
preceding 3 months (hereafter referred to as current injection),
and midazolam (a benzodiazepine commonly used by IDUs inFigure 1. Distribution of the 19 gathering places with pie charts showing the proportioHong Kong) injection;22 (4) methadone treatment: ﬁrst year on
treatment and current frequency of methadone use; and (5)
awareness of their anti-HCV status. An incentive was provided in
the form of a HK$30 coupon on completion of each survey
(US$1 = HK$7.8).
2.2. Testing for HCV antibody
A ﬁnger prick peripheral blood sample was collected from each
respondent using a single-use lancet, which was blotted onto a
Protein Saver 903 Card (Whatman) to completely ﬁll the pre-
printed circles. The blood spots were allowed to air dry and were
transported to the laboratory on the same day.
To test for the presence of HCV antibody, a 6-mm spot was
punched from the dried blood spot and suspended in 200 ml of
phosphate-buffered saline in the well of a ﬂat-bottomed uncoated
microtiter plate. The plate was incubated at 4 8C for 2 h and
subsequently 150 ml of the eluate was used as the specimen for
testing.23 Eluted dried blood spots were tested for HCV antibody by
a commercial ELISA kit (Murex Anti-HCV, version 4.0; Abbott).
Positivity was deﬁned in accordance with the manufacturer’s
recommendations.
2.3. Statistical analyses
The associations between the anti-HCV test result and
individual variables were measured by odds ratio (OR) with 95%
conﬁdence interval (CI). Linear logistic regression by backward
maximum likelihood ratio test was carried out in PASW Statistics
18 for Windows (SPSS Inc., Chicago, IL, USA) to explore factors
associated with HCV antibody test results. Demographics and drugns of positive and negative hepatitis C antibody test results, sized by sample size.
Table 1
Characteristics of injection drug users (N = 622)
Characteristics n (%)
Demographics
Age, years, median (1st–3rd quartile) 53 (44–60)
Age below 65 years 570 (91.6)
Male gender 527 (84.7)
Drug use/behavior history
First heroin use:a
Before 1980 269 (43.3)
1980–1989 200 (32.2)
1990–1999 128 (20.6)
After 1999 24 (3.9)
First heroin use by needle injection:
Before 1980 155 (24.9)
1980–1989 185 (29.7)
1990–1999 169 (27.2)
After 1999 113 (18.2)
Needle-sharingb 428 (69.1)
Midazolam injection 353 (56.8)
Current heroin injection 442 (71.1)
Methadone treatment
Methadone treatment duration:a
<5 years 44 (7.2)
5–9 years 32 (5.2)
10–19 years 139 (22.7)
>19 years 397 (64.9)
Current methadone treatment frequency:a
No treatment 60 (9.7)
Once per month 2 (0.3)
Once per week 5 (0.8)
2–3 times per week 32 (5.1)
Almost every day 522 (84.1)
HCV antibody result
Positive 508 (81.7)
Aware of HCV infection 125 (20.1)
a Data missing for one IDU.
b Data missing for three IDUs.
Table 2
Factors associated with a positive HCV antibody test result (N = 622)
HCV antibody test
result
Positive
(%)
Negative
(%)
OR 95% CI
Demographics
Age below 65 years 92.5 87.7 1.73 0.90–3.32
Male gender 85.8 79.8 1.53 0.91–2.58
Drug use/behavior history
Heroin use 20 yearsa 86.4 71.1 2.59d 1.60–4.17
Drug injection 20 years 71.9 45.6 3.04d 2.01–4.61
Needle-sharingb 73.1 51.8 2.53d 1.67–3.84
Midazolam injection 64.0 24.6 5.46d 3.43–8.67
Current heroin injection 77.4 43.0 4.53d 2.96–6.93
Methadone treatment
20 yearsa 68.1 50.0 2.13d 1.40–3.25
Current methadone treatment
frequencya
No treatment 8.5 14.9 0.53d 0.29–0.97
Non-frequentc 6.1 7.0 0.86 0.39–1.93
Almost every day 85.4 78.1 1.64 0.99–2.73
OR, odds ratio; CI, conﬁdence interval.
a Data missing for one IDU.
b Data missing for three IDUs.
c Once per month, once per week, and 2–3 times per week.
d p < 0.05.
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of methadone treatment was excluded because almost all
respondents had been on methadone, and that treatment duration
overlapped with the drug injection duration.
To test for the heterogeneity of anti-HCV seroprevalence in
gathering places, multilevel logistic regression24–26was performed
using R (R Foundation for Statistical Computing, Vienna, Austria;
version 2.13.2), MASS, and NLME packages. The multilevel model
was applied at the individual level and then gathering place level.
Two types of model were constructed: the empty model
incorporating only anti-HCV positivity as the outcome, and
explanatory models expanded from the empty model to take in
statistically signiﬁcant factors from the linear logistic regression
analysis. The degree of variation in gathering places was measured
by median odds ratio (MOR) and proportional change in variance
(PCV). A MOR of 1 is indicative of an absence of area difference,
while a value >1 denotes a stronger area difference. PCV24
quantiﬁes the proportion of gathering place level variance of the
empty model explainable by factors input into the explanatory
model. Wald statistics was used to examine the necessity of the
multilevel logistic model to explain the variation.26
3. Results
3.1. Proﬁle of enrolled IDUs
A total of 19 gathering places in Hong Kong were identiﬁed by
trained volunteers, which were at a distance of 12 to 305 m from
the nearest methadone clinic (Figure 1). About two-thirds (68%)
were within 100 m of the nearby clinic. Between August and
September 2011, 640 drug users were enrolled, 18 of whom were
excluded because of failure to meet enrolment criteria (n = 4),
incomplete questionnaires (n = 4), and duplication (n = 10). The
ﬁnal sample size for analysis was 622 (97.2%), which was
equivalent to the summation of almost all IDUs at each gathering
place at selected timeslots during the enrolment period, account-
ing for 21% of the total estimated number of drug users frequenting
the 19 gathering places at all times.
Characteristics of the enrolled drug users are shown in Table 1.
A majority of the respondents were male (84.7%) and the median
age of all the IDUs was 53 years (range 29–79 years). All
respondents gave a history of heroin use and the practice of
injection behavior. The median duration of heroin use was 30 years
(interquartile range (IQR) 22–39 years). The median duration of
heroin injection practice was 25 years (IQR 15–31 years), with half
initiating injection between 1980 and 1996. Some 70% were
currently injecting heroin at the time of the survey, while 56.8%
gave a history of midazolam injection. Needle-sharing was
reported in 69.1% of the IDUs. Almost all respondents (98.6%)
were on methadone treatment and 84.1% visited a methadone
clinic almost every day.
3.2. HCV infection and its associated factors
All respondents (n = 622) provided dried blood spot specimens
for HCV antibody testing. The anti-HCV seroprevalence was 81.7%
(n = 508, 95% CI 78.6–84.7%). Around a ﬁfth of the respondents
were aware of their HCV status (either positive or negative). On
bivariate analysis, age and gender were not signiﬁcantly associated
with the anti-HCV test result (Table 2). There was, however, a
statistically signiﬁcant association between HCV infection and the
following drug use behaviors: midazolam injection (OR 5.46, 95%
CI 3.43–8.67), current injection (OR 4.53, 95% CI 2.96–6.93), and
history of needle-sharing (OR 2.53, 95% CI 1.67–3.84). Long
durations of heroin use (at least 20 years) (OR 2.59), heroin
injection behavior (OR 3.04), and methadone treatment (OR 2.13),but not the frequency of methadone use, were signiﬁcantly
associated with a positive anti-HCV test result. In the multivariable
logistic regression model, the main determinants were midazolam
injection (adjusted odds ratios (AOR) 4.91, 95% CI 2.89–8.33),
current injection (AOR 2.81, 95% CI 1.72–4.57), and drug injection
for at least 20 years (AOR 4.07, 95% CI 2.52–6.59).
Table 3
Distribution of anti-HCV seroprevalence and associated behavioral factors (midazolam injection, current injection, drug injection duration, and needle-sharing) by gathering
place (n = 19), with odds ratios to demonstrate the strength of association
Code Sample size Anti-HCV
seroprevalence
Midazolam injection
OR (95% CI)
Current injection
OR (95% CI)
Drug injection duration
OR (95% CI)
Needle-sharing
OR (95% CI)
A 1 100.00 - - - -
M 3 100.00 - - - -
K 73 95.89 1.83 (0.16–21.62) 3.00 (0.25–36.26) 0.95 (0.85–1.06) 0.62 (0.05–7.13)
P 29 89.66 0.84 (0.69–1.02) 3.20 (0.26–40.06) 1.25 (1.00–1.56) 0.79 (0.60–1.03)
I 34 85.29 25.00 (2.20–284.61)a 9.38 (1.17–74.84)a 1.06 (0.97–1.16) 3.94 (0.55–28.12)
H 40 85.00 1.39 (0.22–8.93) 6.50 (1.00–42.30)a 1.10 (0.99–1.21) 2.4 (0.41–13.98)
O 80 83.75 2.95 (0.83–10.53) 2.60 (0.73–9.25) 1.06 (1.00–1.13)a 0.88 (0.22–3.59)
G 40 82.50 4.42 (0.48–40.98) 1.50 (0.28–7.91) 1.15 (1.04–1.27)a 0.52 (0.05–5.00)
J 27 81.48 0.375 (0.15–0.92) 9.50 (1.09–82.73)a 1.00 (0.92–1.09) 8.57 (0.80–91.50)
L 27 81.48 4.22 (0.49–36.77) - 1.10 (0.99–1.22) 4 (0.53–30.16)
E 25 80.00 9.33 (0.85–101.95) 1.24 (0.17–9.25) 1.19 (1.01–1.40)a 8.5 (0.97–74.42)
Q 62 79.03 3.88 (1.04–14.41)a 4.48 (1.10–18.28)a 1.05 (1.00–1.11) 1.98 (0.50–7.87)
C 54 77.78 2.52 (0.68–9.34) 7.33 (1.79–30.00)a 1.08 (1.01–1.15)a 2.29 (0.59–8.81)
S 65 73.85 5.83 (1.20–28.37)a 4.38 (1.32–14.52)a 1.01 (0.96–1.07) 5.43 (1.65–17.86)a
N 7 71.43 - - - -
D 10 70.00 - - - -
B 18 66.67 0.46 (0.24–0.87) 6.00 (0.70–51.10) 1.25 (1.00–1.57)a 22 (1.54–314.29)a
F 3 66.67 - - - -
R 24 66.67 0.47 (0.27–0.80) 11.67 (1.14–119.54)a 1.00 (0.93–1.08) 13 (1.70–99.38)a
OR, odds ratio; CI, conﬁdence interval.
a p < 0.05.
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variables in the 19 gathering places are illustrated in Figure 1 and
Table 3. Overall, the anti-HCV seroprevalence varied from a
minimum of 66.7% to a maximum of 100%. The factors associated
with HCV infection and the strengths of association varied across
gathering places. In some gathering places, for example location Q,
anti-HCV was strongly associated with midazolam injection (OR
3.88) and current injection (OR 4.48). In other places, like location
G, drug injection duration (OR 1.50) was the only signiﬁcant factor.
Signiﬁcant factors identiﬁed in the linear logistic regression
model were input into the multilevel model in different
combinations. Three multilevel models were ﬁnally constructed:
(1) an empty model (model one); (2) model two, expanded from
model one after adding long duration of injection (20 years) for
random intercept and random slope; (3) model three, which
included midazolam injection and current injection for random
intercept and midazolam injection for random slope. Model one
gave a moderately signiﬁcant result (Wald statistics = 1.27),
supporting the use of a multilevel model to explain HCV prevalence
in terms of gathering place variation (Table 4). The MOR value
(1.38) in model one supported the presence of a modest area
variation. The inclusion of long duration of injection in model two
was able to explain 11% of the variance in model one and the MOR
was 1.36. The AOR for long duration of injection was 3.17 (95% CITable 4
Measures of association with individual risk factors and variation with gathering plac
hepatitis C infection (n = 598; gathering place = 14)
Model 1 (empty model) 
Measures of association
Adjusted OR (95% CI)
Injection 20 years - 
Midazolam injection - 
Current injection - 
Measures of variation
Gathering place level variance (SE) 0.12 (0.09) 
Slope variance (SE) - 
Covariance between slope and intercept 
Proportional change in variance (PCV) - 
Median odds ratio (MOR) 1.38 
OR, odds ratio; CI, conﬁdence interval; SE, standard error.
a Midazolam injection as random slope.2.02–4.99). With the incorporation of midazolam injection and
current heroin injection in model three (Wald statistics = 1.23), the
MOR was 1.37. The AOR for ever practicing midazolam injection
was 3.91 (95% CI 2.30–6.63) and for current injection was 2.88 (95%
CI 1.81–4.58). The two factors explained 7% of the variance in
model one.
4. Discussion
In this study we report an anti-HCV seroprevalence of 81.7% in
IDUs in Hong Kong, a ﬁgure comparable to that of a similar survey
conducted 5 years ago (85%).8 Compared to the estimated global
midpoint prevalence of 67% in 2010,27 Hong Kong has a relatively
high level of HCV infection. However, despite the small area of the
territory of Hong Kong, HCV was not evenly distributed in IDUs.
Among 19 gathering places distributed throughout the city, HCV
seroprevalence was below 67% in three places and above 80% in 10
(Table 3). In addition to behavioral factors commonly reported to
be associated with HCV infection, we used multilevel models to
better explain the heterogeneous distribution of anti-HCV
seropositivity. We conclude therefore that the probability of
HCV infection is a function of the gathering place an IDU belongs to,
adjusted by place-speciﬁc behavioral factors.e by multilevel logistic random intercept and random slope regression models of
Model 2 Model 3
3.17 (2.02–4.99); p < 0.01
- 3.91 (2.30–6.63); p < 0.01
- 2.88 (1.81–4.58); p < 0.01
0.10 (0.09) 0.11 (0.09)
0.10 (0.08) 0.11 (0.09)a
0.52 0.88
0.11 0.07
1.36 1.37
N.S. Wong et al. / International Journal of Infectious Diseases 17 (2013) e193–e198 e197As a bloodborne virus, the association between HCV and
injection behaviors has been well established. In our study, a long
duration of drug injection (20 years) was signiﬁcantly associated
with HCV infection in a linear logistic regression model. A long
duration of injection implies a long exposure time for virus
transmission to occur, as reported in other similar studies.8 Long
injection duration was a signiﬁcant factor for HCV infection in the
multilevel model, and the covariance of slope and intercept was
positive (0.52). The variation in HCV in shorter injection duration
IDUs by gathering place was smaller than in IDUs with a long
injection duration. Likewise, current injection could be viewed as a
surrogate for frequent injection and was positively associated with
needle-sharing (OR 2.91, 95% CI 2.02–4.20). There was a strong
association between current injection and an anti-HCV-positive
result in the linear regression model (AOR 3.32) and multilevel
model (AOR 2.88). Surprisingly, needle-sharing was not a
signiﬁcant factor, a phenomenon that might be related to the
misconception by some that the common use of injection
equipment does not amount to ‘sharing’,28,29 a practice that could
have been underreported. On the other hand, the difference may be
too small for explaining the variation in HCV prevalence across
gathering places.
The variation in HCV prevalence by gathering place can be
explained by the transmission pattern of the virus. As a human
pathogen, transmission of HCV occurs when a vulnerable IDU is
exposed to an infected person sharing the same injection
behaviors. The intensity of exposure is a necessary but insufﬁcient
condition for infection to occur. Frequent injection and needle-
sharing would not lead to HCV transmission unless the virus is
circulating in the same community. We have previously reported
the low spatial mobility of IDUs in Hong Kong, an observation that
lends support to the maintenance of discrete social networks of
drug-taking populations.30 In the current study, we speciﬁcally
inquired about the use of midazolam injection as a signature
behavior in IDU networks. Midazolam is a benzodiazepine with a
rapid onset and short duration of action.31 As a cheap and easily
accessible drug compared to heroin,32 midazolam is reportedly
used with heroin33 to achieve euphoria. As a learned behavior, the
administration of midazolam by injection acted both as a signature
character and an add-on risk factor for HCV infection. In our study,
75% of IDUs injecting midazolam had shared needles compared to
62% of non-midazolam using IDUs (OR 1.81, 95% CI 1.28–2.55). The
strength of association of midazolam injection with HCV varied
across gathering places. On multilevel analysis, the impact of
midazolam injection was stronger in gathering places with a low
rather than high intercept (covariance of slope and inter-
cept = 0.88). The HCV infection risk of non-midazolam using
IDUs was therefore strongly affected by the gathering place they
belonged to. However, for IDUs injecting midazolam, the variation
in prevalence among gathering places narrowed, and even IDUs in
lower intercept gathering places had a high risk of infection due to
the strong inﬂuence of midazolam.
In arriving at these conclusions, our study carries some
limitations. First of all, the target population was limited to IDUs
in gathering places. While the study managed to cover about a ﬁfth
of the heroin users visiting gathering places, the latter accounted
for about half of all reported heroin users in Hong Kong in 2010.19
The other half of the heroin users were not approached, as they
might have been taking drugs at home or at friend’s places rather
than in public gathering places.19 Results derived in the current
study may therefore not be extrapolated to the entire drug-taking
community. Secondly, the social networks of the IDUs were
identiﬁed by the individuals’ afﬁliation with gathering places only,
while characteristics such as network size, contact pattern, and
history of membership were not collected in the survey. Thirdly,
the HCV antibody tests performed on dried blood spot specimenscould only allow us to evaluate factors associated with a history of
HCV infection without knowledge of whether these were active
infections or not. The transmission potential of the enrolled IDUs
may vary over time and also from person to person, and the
implications of this were not incorporated into the models.
In conclusion, the application of multilevel models showed that
there was heterogeneity in anti-HCV seroprevalence in Hong Kong
at two levels, as suggested by the variability by individual level
behavioral factors and at the group level by gathering places.
Prevention and control measures would need to be developed not
just by considering the practice of high-risk drug-taking behaviors
in IDUs, but also their interactive relationships within community
networks. With improvements in HCV treatment outcomes, the
planning of clinical services is becoming an important strategy for
meeting the needs of people infected with the virus. In this regards,
knowledge of the prevalence at the local level would be invaluable
for the development of effective interventions, both for reducing
morbidity associated with HCV infection and for minimizing its
spread in IDU communities.
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